Until now, there are only two FGFR-targeted drugs approved for clinical use in bile duct cancer, and both of them are small-molecule inhibitors—erdafinitib (against FGFR2-3 overexpressed in prostate cancer) (Hoy, 2020) and pemigatinib for FGFR aberrations (Markham, 2019). This evidence concerns the gene FGFR2 and bile duct cancer.